复宏汉霖(Henlius)宣布,其注射用HLX43联合HLX07及汉斯状(Hansizhuang)的临床试验申请已获得监管机构批准。这一进展标志着公司在创新药物研发领域迈出重要一步,为后续临床研究奠定基础。
复宏汉霖(Henlius)宣布,其注射用HLX43联合HLX07及汉斯状(Hansizhuang)的临床试验申请已获得监管机构批准。这一进展标志着公司在创新药物研发领域迈出重要一步,为后续临床研究奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.